A book of collected works and publications of the author, 2004–2025.

 The purpose of the publication is to implement the most important projects, such as non-narcotic anticancer cannabinoids of various physicochemical and pharmacological groups, and antibiotics with a fundamentally new strategy for implementing antibiotic action, antibiotics of the post-micromycete era. As well as a number of other projects in the field of pharmacology, light industry, food and agricultural industries.

The author does not have a scientific degree, and has been conducting independent research activities since 2004. Has a higher education as a certified specialist in the field of pharmacological and biotechnological industries, worked as an organic synthesis chemist in several laboratories. The main type of employment is research.

 The author practically does not refer to  references, since the author's works are often innovative, and the official requirements for compiling works do not correspond to the very essence of the author's works. The author also does not waste time writing extensive works, since most of the author's time and effort is spent on achieving a result or overcoming the path from the unknown to the discovery.

 Since the author's goals are extremely pragmatic, the style of presentation of the material is similar to that which is more often stored in the safe of a pharmaceutical company than in an official scientific paper; it is an internal workshop directive written in a popular science style of presentation.

 The author wrote a paper on synthetic pro-cannabinoid anticancer anthocyanins, probably before a similar group of substances was found in plant materials, the author was the first in the world to publish a pharmacological scheme of picrocrocin (the active substance of Crocus Sativus).

 A brief digression, I know it's hard to believe. This is a book about science, you can always check it if you master the material. Tell me, which of the two teachers is the real one, the one who had great teachers or the one who didn't have any at all? I don't know what "real" means to you, but I can definitely tell you who was the First.

 The author was the first to publish a paper on ultra-light cannabinoids (much weaker than marijuana), the first to publish a pharmacological scheme of alpha-terpineol and amantadine. The author was the first to publish examples of anti-cancer cannabinoids that do not pass the blood-brain barrier.

 The first to publish a paper on the pseudo-complex behavior of affinity molecules on biopolymers. The first to outline a theoretical path to post-micromycete antibiotics, using pseudo-complex multi-component substances and irreversible denaturation of the main pathogen protein as an example.

 Despite such a high declared track record and such high goals, the author's works have a number of shortcomings, these are often inaccuracies in punctuation and different styles of presentation of visual material. Such shortcomings are due to the fact that the works were translated from their native language using Google Translate, and in different periods of time.

 Also, the main disadvantage of the work of an independent researcher today is the difficulty in setting up studies.

 The latter significantly narrows the experimental part of the work. The author, of course, was engaged in research and received certain results, tested completely new substances, structures of a completely new design, new cores, new tactics and strategies of drug design.    

Such studies were carried out mainly in relation to light drugs, such as physiologically active alcohols, also high-affinity derivatives of new drug design cores and some others.

 The results obtained served as a compass for the formation of unique methods of drug design, new approaches and the discovery of unknown groups of substances, the formation of a theoretical basis for the development of completely new strategies of drug design.

 I hope to get a lot of your precious time, and I hope for a great result. We will implement all priority projects, improve the connection between pharmacology and society. The specialty of drug designer will become less private and rare, pharmacology will have more feedback.